Human growth, growth disorders and treatments

2017 ◽  
pp. 42-45
Author(s):  
Ben Greenstein
2009 ◽  
Vol 05 (0) ◽  
pp. 47 ◽  
Author(s):  
Tomasz E Romer ◽  

Since ancient times plant and animal tissues have been used as medicines. In the 20th century growth hormone as a purified extraction from human pituitaries was still used to treat growth disorders. Since the genetic engineering of host cells became possible, a new generation of medicines obtained using recombinant DNA (rDNA) technology has emerged. These medicines have been named ‘biopharmaceuticals’. The first biopharmaceutical growth hormones were patented in the 1980s, so already over two decades of clinical experience support the development of a new, off-patent growth hormone preparation obtained by rDNA technology. The European Medicines Agency (EMEA) has put in place a centralised procedure for the approval of new biopharmaceuticals. This procedure includes testing comparability with a reference product and demands post-approval pharmacovigilance. Omnitrope® was the first off-patent recombinant human growth hormone (rhGH) approved on the basis of the biosimilar pathway; it underwent a very demanding approval procedure in 2006 and is now used for several indications in Europe, the US, Canada, Japan, Australia and other countries where it has received marketing approval.


2006 ◽  
Vol 66 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Ryan P. Clark ◽  
Mark Schuenke ◽  
Stephanie M. Keeton ◽  
Robert S. Staron ◽  
John J. Kopchick

2018 ◽  
Vol 103 (9) ◽  
pp. 3155-3168 ◽  
Author(s):  
Michael H Guo ◽  
Joel N Hirschhorn ◽  
Andrew Dauber

Abstract Context In the last decade, genome-wide association studies (GWASs) have catalyzed our understanding of the genetics of height and have identified hundreds of regions of the genome associated with adult height and other height-related body measurements. Evidence Acquisition GWASs related to height were identified via PubMed search and a review of the GWAS catalog. Evidence Synthesis The GWAS results demonstrate that height is highly polygenic: that is, many thousands of genetic variants distributed across the genome each contribute to an individual’s height. These height-associated regions of the genome are enriched for genes in known biological pathways involved in growth, such as fibroblast growth factor signaling, as well as for genes expressed in relevant tissues, such as the growth plate. GWASs can also uncover previously unappreciated biological pathways, such as theSTC2/PAPPA/IGFBP4 pathway. The genes implicated by GWASs are often the same genes that are the genetic causes of Mendelian growth disorders or skeletal dysplasias, and GWAS results can provide complementary information about these disorders. Conclusions Here, we review the rationale behind GWASs and what we have learned from GWASs for height, including how it has enhanced our understanding of the underlying biology of human growth. We also highlight the implications of GWASs in terms of prediction of adult height and our understanding of Mendelian growth disorders.


1990 ◽  
Vol 70 (3) ◽  
pp. 687-692 ◽  
Author(s):  
ROSEMARIE LAJARA ◽  
JOHN P. GALGANI ◽  
DAVID P. DEMPSHER ◽  
DENNIS M. BIER ◽  
PETER ROTWEIN

Sign in / Sign up

Export Citation Format

Share Document